TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06254183

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin is a drug that is commonly used to treat neuropathic pain, epilepsy, and other neurological disorders. According to some studies, gabapentin may affect the Wnt signaling pathway.~In this study Gabapentin will be given by a dose of 1200 mg 1 hour before a laparoscopic sleeve gastrectomy(LSG) to decrease postoperative pain and opioid consumption. As acute kidney injury is a common condition following LSG , and as gabapentin has a positive effect on decreasing AKI induced in animal studies, we assess the effect of gabapentin on the AKI status following LSG

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo is a sham medical treatment that appears to be a real medical intervention but has no therapeutic effect. It is often used in clinical trials to compare the effects of a new treatment to those of a placebo. Common examples of placebos include inert tablets (like sugar pills), inert injections (like saline), and even sham surgery or other procedures. Placebos are typically made of inactive substances such as starch or sugar and are designed to be indistinguishable from the actual treatment
Study: NCT05647837

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: lumper puncture
Description: lumper puncture
Study: NCT04079231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brolucizumab
Description: Intravitreal Injection
Study: NCT05307835

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iNeo-Vac-P01
Description: iNeo-Vac-P01 (peptides)： 4 x 300 mcg per peptide given on days 1, 4, 8, 15, 22, 52, and 82 for a total of 7 doses;

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 4 x 40 mcg (total dose 160 mcg) given on days 1, 4, 8, 15, 22, 52, and 82 for a total of 7 doses
Study: NCT04079231

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Intravitreal injection
Study: NCT06057974

Intervention type: OTHER
Intervention: Close Collaboration with Parents
Description: The Close Collaboration with Parents intervention is an educational model for healthcare staff working in NICUs. It aims to improve the ability of the members of the NICU healthcare team to I) observe the infants' individual behaviors and needs, II) support parents to take the initiative and share their observations and understanding of their infant's behaviors and to collaboratively plan the infant's care with the healthcare staff, III) understand the individual story of the family regarding parenthood through a dialogue with parents, and IV) involve parents in the decision-making about the care of their baby from an early stage of care through to the preparation for discharge. The final goal is to improve the care culture in the NICUs by changing the attitudes of the healthcare staff and the care practices of the unit to be more in line with family-centered care principles.~It usually takes 1.5 years for each NICU to complete the intervention.
Study: NCT04148482

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary intervention
Description: To investigate whether individuals with divergent genetic susceptibility have different food preferences and have differential post-prandial glycemic and metabolomics responses to a standardized or an election meal.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention
Description: To investigate whether individuals with divergent genetic susceptibility have different food preferences and have differential post-prandial glycemic and metabolomics responses to a standardized or an election meal.
Study: NCT05858879

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Notification of patients and clinicians
Description: Notification Patients randomized to notification will receive a message sent by either the electronic health record (EHR) patient portal or US mail that will inform them of the CAC identified on their previous chest CT scan and a recommendation that they discuss this finding and initiation of lipid-lowering therapy with their clinician. The clinicians will be notified of these findings by an earlier EHR message that will be sent 2 weeks before the patient notification.~Usual Care The usual care arm will not receive any additional notification beyond this standard of care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Notification of patients and clinicians
Description: Notification Patients randomized to notification will receive a message sent by either the electronic health record (EHR) patient portal or US mail that will inform them of the CAC identified on their previous chest CT scan and a recommendation that they discuss this finding and initiation of lipid-lowering therapy with their clinician. The clinicians will be notified of these findings by an earlier EHR message that will be sent 2 weeks before the patient notification.~Usual Care The usual care arm will not receive any additional notification beyond this standard of care.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Notification of patients and clinicians
Description: Notification Patients randomized to notification will receive a message sent by either the electronic health record (EHR) patient portal or US mail that will inform them of the CAC identified on their previous chest CT scan and a recommendation that they discuss this finding and initiation of lipid-lowering therapy with their clinician. The clinicians will be notified of these findings by an earlier EHR message that will be sent 2 weeks before the patient notification.~Usual Care The usual care arm will not receive any additional notification beyond this standard of care.
Study: NCT06033105

Intervention type: DEVICE
Intervention: ELISA
Description: Enzyme-linked immunosorbent assay (ELISA) was used following manufacturer's instructions. This test uses a competitive ELISA-based technique that was designed to quantitatively determine the concentration of 1,25-dihydroxyvitamin D3/D2 in human serum.

Intervention type: DEVICE
Intervention: ELISA
Description: Enzyme-linked immunosorbent assay (ELISA) was used following manufacturer's instructions. This test uses a competitive ELISA-based technique that was designed to quantitatively determine the concentration of 1,25-dihydroxyvitamin D3/D2 in human serum.
Study: NCT06518551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Humanized, recombinant IgG1 monoclonal antibody, 400- and 300-mg single-use vials, via intravenous (into the vein) infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Humanized, recombinant IgG1 monoclonal antibody, 400- and 300-mg single-use vials, via intravenous (into the vein) infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: A cereblon E3 ligase modulator, 0.15mg, 0.2mg, 0.3mg, 0.45mg, 0.6, and 0.75 mg strength capsule taken orally per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: A cereblon E3 ligase modulator, 0.15mg, 0.2mg, 0.3mg, 0.45mg, 0.6, and 0.75 mg strength capsule taken orally per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Synthetic adrenocortical steroid, 2 and 4 mg tablets, taken orally per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Synthetic adrenocortical steroid, 2 and 4 mg tablets, taken orally per standard of care.
Study: NCT06471322

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Glucose Monitoring (CGM)
Description: Patients will wear a continuous glucose monitor upon discharge from the hospital for six months
Study: NCT05299216

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Diaphragm Technique
Description: Treatment group will receive Manual Diaphragm Technique in addition to Conventional Physical Therapy. Therapist will make physical contact to the underside of the 7th to 10th rib costal cartilages. During the inspiratory phase, the therapist will use both hands to gently pull the points of contact in the direction of the head. During exhalation, the therapist will maintain resistance. The procedure will be done in two sets of ten deep breaths, separated by a one-minute pause.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy
Description: Conventional Physical Therapy group comprises electrotherapeutic treatment and exercise plan. Subjects will undergo a thermal continuous ultrasound, conventional transcutaneous electrical nerve stimulation and a hot pack.~Stretching activities for the back, iliopsoas, and hamstring muscles, as well as abdominal muscle strengthening exercises, will be included in the workout.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Conventional Physical Therapy group comprises electrotherapeutic treatment and exercise plan. Subjects will undergo a thermal continuous ultrasound, conventional transcutaneous electrical nerve stimulation and a hot pack.~Stretching activities for the back, iliopsoas, and hamstring muscles, as well as abdominal muscle strengthening exercises, will be included in the workout.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham Diaphragm Manual Technique
Description: The Control group will also receive a sham diaphragm release technique. The therapist and participant will have the same manual contacts, duration, and placement as the treatment group, but the therapist will simply use a light touch with the same anatomical landmarks and will not apply pressure.
Study: NCT05051722

Intervention type: DIAGNOSTIC_TEST
Intervention: Tampon Collection
Description: A tampon will be self-inserted by each participant prior to any exams or procedures and removed after 40 minutes..

Intervention type: DIAGNOSTIC_TEST
Intervention: Tampon Collection
Description: A tampon will be self-inserted by each participant prior to any exams or procedures and removed after 40 minutes..

Intervention type: DIAGNOSTIC_TEST
Intervention: Tampon Collection
Description: A tampon will be self-inserted by each participant prior to any exams or procedures and removed after 40 minutes..

Intervention type: DIAGNOSTIC_TEST
Intervention: Tampon Collection
Description: A tampon will be self-inserted by each participant prior to any exams or procedures and removed after 40 minutes..

Intervention type: DIAGNOSTIC_TEST
Intervention: Tampon Collection
Description: A tampon will be self-inserted by each participant prior to any exams or procedures and removed after 40 minutes..

Intervention type: DIAGNOSTIC_TEST
Intervention: Tampon Collection
Description: A tampon will be self-inserted by each participant prior to any exams or procedures and removed after 40 minutes..

Intervention type: DIAGNOSTIC_TEST
Intervention: Tampon Collection
Description: A tampon will be self-inserted by each participant prior to any exams or procedures and removed after 40 minutes..

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Collection
Description: A blood sample will be collected from each participant prior to undergoing any exams or procedures.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Collection
Description: A blood sample will be collected from each participant prior to undergoing any exams or procedures.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Collection
Description: A blood sample will be collected from each participant prior to undergoing any exams or procedures.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Collection
Description: A blood sample will be collected from each participant prior to undergoing any exams or procedures.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Collection
Description: A blood sample will be collected from each participant prior to undergoing any exams or procedures.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Collection
Description: A blood sample will be collected from each participant prior to undergoing any exams or procedures.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Collection
Description: A blood sample will be collected from each participant prior to undergoing any exams or procedures.
Study: NCT06314659

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Zhifei Lvzhu)
Description: Performed primary immunization following a 0-1-2-month schedule at the aged from 3 to 5 months and booster immunization at 18 months of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Zhifei Lvzhu)
Description: Performed primary immunization following a 0-1-2-month schedule at the aged from 3 to 5 months and booster immunization at 18 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Walvax)
Description: Performed primary immunization following a 0-1-2-month schedule at the aged from 3 to 5 months.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Olymvax)
Description: Performed booster immunization at 18 months of age.
Study: NCT04802031

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rapid Infusion Isatuximab
Description: Given IV
Study: NCT05558137

Intervention type: DRUG
Intervention: Mivacurium
Description: 0.2 mg/kg based on ideal body weight calculated as height (cm) minus 105 for women and height (cm) minus 100 for men or actual body weight, whichever is lower

Intervention type: DRUG
Intervention: Mivacurium
Description: 0.2 mg/kg based on ideal body weight calculated as height (cm) minus 105 for women and height (cm) minus 100 for men or actual body weight, whichever is lower
Study: NCT05631340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discharge education
Description: Researcher's newly prepared discharge education supported by a booklet and mobile app

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Discharge education
Description: Researcher's newly prepared discharge education supported by a booklet and mobile app
Study: NCT04114708

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Anterior cruciate ligament Reconstruction (ACLR)
Description: All patients will undergo an anatomic ACLR via a standardized fashion using BTB autograft.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ACLR with lateral extra-articular tenodesis (LET)
Description: All LETs will be performed in a standardized fashion using the modified Lameire technique. All patients will undergo an anatomic ACLR via a standardized fashion using BTB autogaft graft.
Study: NCT05182658

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 MG
Description: The proposed intervention will be administration of empagliflozin at a standard dose of 10 mg daily for a period of 12 months. Patients with diagnosed diabetes will be excluded from the study. Patients (n = 250) will be randomized in a double-blind fashion to empagliflozin or placebo group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The proposed intervention will be administration of placebo for a period of 12 months. Patients (n = 250) will be randomized in a double-blind fashion to empagliflozin or placebo group.
Study: NCT05260476

Intervention type: OTHER
Intervention: Reablement
Description: The service provider customizes a training plan and formulates training goals based on the patient's level of disability, family environment, and the needs of the patient and the caregiver.

Intervention type: OTHER
Intervention: Reablement
Description: The service provider customizes a training plan and formulates training goals based on the patient's level of disability, family environment, and the needs of the patient and the caregiver.
Study: NCT06471322

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of Care - retrospective review
Study: NCT05747014

Intervention type: DEVICE
Intervention: Novapak Nasal Sinus Packing and Stent
Description: Potential subjects will have the need to undergo nasal/sinus surgery using a space-occupying stent and will perform daily self-saline nasal irrigations.
Study: NCT05027581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bone marrow mesenchymal stem cells
Description: The bone marrow mesenchymal stem cells (BM-MSCs) in Chondrochymal® for this study was obtained from the donor recruited in Taipei Veterans General Hospital, Taiwan. Donors aged 20 to 50 and tested negative to infection of human immunodeficiency virus type 1 and 2 (HIV-1/2), hepatitis B virus (HBV), hepatitis C virus (HCV), Cytomegalovirus (CMV), Treponema pallidum (syphilis), human T-lymphotropic virus types I and II (HTLV-I/II), and Tuberculosis (TB) were enrolled. The eligible donor's bone marrow was aspirated from the iliac crest or femur. The collected BM-MSCs were then cultured, expanded and cryopreserved in a Good Tissue Practice (GTP)-complied laboratory. The qualified cells in cryopreservation meeting the release criteria will be thawed, mixed with lactated Ringer's solution, and transferred into a sterile syringe as the final product.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyaluronic acid
Description: (60 mg/3 mL hyaluronic acid \[HA\])
Study: NCT04626037

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WECS Relational Toolkit
Description: The Cuddle and Calm Book, The Mommy Baby Book, mother and child mutual narrative, the Bottle of Emotions, and the WECS for emotional connection, make up the WECS Relational Health toolkit.
Study: NCT05242562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plenvu
Description: a recently developed 1 liter bowel preparation fluid that is often used in clinical practice. Patients will receive a split dose protocol, low-residue diet 2 days before colonoscopy, and clear liquid diet 1 day before colonoscopy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moviprep
Description: a 2 liter widely established 2 liter bowel preparation fluid that is commonly used in clinical practice. Patients will receive a split dose protocol, low-residue diet 2 days before colonoscopy, and clear liquid diet 1 day before colonoscopy.
Study: NCT04926597

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nutritional supplement
Description: daily use of one or more specific oral nutritional supplement with high energy/protein content (i.e., Resource Ultra, Resource 2.0 (Fibre), Resource Ultra Fruit).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: individualized nutritional guidelines
Description: nutritional plan supervised by an experienced study dietician based on the usual home nutrition with possibility to increase intake by adaptation to patient preferences, between meal snaking and food enrichment/fortification. Every 2-4 weeks phone call by unblinded study dietician to follow nutritional intervention.

Intervention type: OTHER
Group type: OTHER
Intervention: general nutritional information
Description: general information about health food behavior upon hospital discharge
Study: NCT05286788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib Oral Tablet [Mektovi]
Description: Binimetinib oral continuous dosing 32 mg/m2 PO BID for 4 weeks
Study: NCT06490939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efepoetin Alfa
Description: Single-intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efepoetin Alfa
Description: Single-intravenous administration
Study: NCT05597943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Malama App
Description: The Malama smartphone application is a gestational diabetes management app that syncs directly with commercially-available glucometers via Bluetooth, enabling both automatic blood glucose logging and providing interactive diet management/diet education tools. We aim to perform a pilot study assessing the impact of the Malama smartphone application on perinatal and postpartum outcomes in patients with GDM.
Study: NCT05668130

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sacrospinous ligament fixation
Description: Women with stage II or higher pelvic organ prolapse with apical compartment involvement planned for surgical management will be randomised to either sacrospinous ligament fixation arm or uterosacral ligament suspension arm. those raandomized to sacrospinous ligament fixation arm will undergo unilateral (right) sided sacrospinous ligament fixation of apex as a part of pelvic organ prolapse surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterosacral Ligament Suspension
Description: Similarly women randomised to uterosacral ligament suspension arm will undergo modified high uterosacral ligament suspension of apex. Both arms will be followed up in 6 months and 12 months for anatomical and functional outcome.
Study: NCT06104423

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol 5 mg
Description: 1 tablet of study medication to be administered orally according to instructions of Investigator.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol 5 mg
Description: 1 tablet of study medication to be administered orally according to instructions of Investigator.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril 2.5/5/10 mg
Description: 1 tablet of study medication to be administered orally according to instructions of Investigator.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril 2.5/5/10 mg
Description: 1 tablet of study medication to be administered orally according to instructions of Investigator.
Study: NCT04594317

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low level laser therapy
Description: buccal application of diode laser on non-contact mode

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low level laser therapy
Description: buccal application of diode laser on non-contact mode
Study: NCT04714827

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KQ-2003 CAR-T cells
Description: A autologous doping CAR - T cells injection targets with CD19 and BCMA，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion KQ-2003 CAR-T cells .

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KQ-2003 CAR-T cells
Description: A autologous doping CAR - T cells injection targets with CD19 and BCMA，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion KQ-2003 CAR-T cells .

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KQ-2003 CAR-T cells
Description: A autologous doping CAR - T cells injection targets with CD19 and BCMA，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion KQ-2003 CAR-T cells .

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KQ-2003 CAR-T cells
Description: A autologous doping CAR - T cells injection targets with CD19 and BCMA，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion KQ-2003 CAR-T cells .